SCHEMBL24068077

SCHEMBL24068077

C=C(C)c1cnc2c(Cl)cc(C(C)(F)F)cn12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.33
▸ KMT2A Q03164 4/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ STAT3 P40763 1/20 0.33
▸ STAT1 P42224 1/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ RXRA P19793 6/20 0.31
▸ GRIN1 Q05586 6/20 0.31
▸ GRIN2B Q13224 6/20 0.31
▸ CYP1A2 P05177 2/20 0.31
▸ CYP2C19 P33261 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24068030 0.90 SMN1; SMN2 (0.40) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL25730229 0.86 RXRA (0.31) RXRAGRIN1GRIN2B
SCHEMBL24068172 0.80 KDM4E (0.32) ALDH1A1NPSR1KDM4ECYP3A4LMNA
SCHEMBL24068039 0.79 SMN1; SMN2 (0.39) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL24068040 0.77 NPC1 (0.36) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL24068097 0.75 RAB9A (0.34) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL25730386 0.74 — —
SCHEMBL24068092 0.68 SMN1; SMN2 (0.46) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL25730233 0.66 — —
SCHEMBL24068093 0.65 SMN1; SMN2 (0.45) MEN1KMT2AALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115667257-B Compounds for inhibiting CDK7 伊莱利利公司 2024-06-11 — — CN disclosed
US-20230203031-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 ELI LILLY AND COMPANY 2023-06-29 — — US disclosed
US-20230203031-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 ELI LILLY AND COMPANY 2023-06-29 — — US disclosed
US-20230203031-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 ELI LILLY AND COMPANY 2023-06-29 — — US disclosed
EP-4157840-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 Eli Lilly and Company (US) 2023-04-05 — — EP disclosed
CN-115667257-A Compounds for inhibiting CDK7 伊莱利利公司 2023-01-31 — — CN disclosed
WO-2021242602-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 ELI LILLY AND COMPANY (US) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203031-A1 COMPOUNDS USEFUL FOR INHIBITING CDK7 CDK7, CDK3, CCNH MEN1 1825/4885KMT2A 357/4885ALDH1A1 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback